Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.45 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.45 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.45 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.38 |
| ▸ | WNT1 | P04628 | 9/20 | 0.37 |
| ▸ | ABL1 | P00519 | 4/20 | 0.36 |
| ▸ | BCR | P11274 | 3/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667784 | 0.83 | ROCK2 (0.65) | GSK3BDYRK3ROCK2MAPK1CLK2 | |
| SCHEMBL660243 | 0.78 | MAP2K4 (0.45) | GSK3ACLK4MAP2K4ABL1SMARCA2 | |
| SCHEMBL13748554 | 0.77 | MAP2K4 (0.44) | MAP2K4ABL1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL29439673 | 0.76 | MAP2K4 (0.48) | GSK3BDYRK3ROCK2MAPK1CLK2 | |
| SCHEMBL22715071 | 0.76 | MAP2K4 (0.48) | GSK3BDYRK3ROCK2MAPK1CLK2 | |
| SCHEMBL29439761 | 0.76 | PDGFRA (0.52) | GSK3BMAP2K4ABL1SMARCA2SMARCA4 | |
| SCHEMBL1943689 | 0.76 | PDGFRA (0.52) | GSK3BMAP2K4ABL1SMARCA2SMARCA4 | |
| SCHEMBL16800567 | 0.76 | MAP2K4 (0.46) | MAP2K4ABL1SMARCA2SMARCA4PBRM1 | |
| SCHEMBL29439666 | 0.75 | MAP2K4 (0.47) | GSK3BDYRK3ROCK2MAPK1CLK2 | |
| SCHEMBL28710646 | 0.75 | MAP2K4 (0.47) | GSK3BDYRK3ROCK2MAPK1CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | GSK3B 1/4885DYRK3 224/4885ROCK2 48/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | GSK3B 1/4885DYRK3 224/4885ROCK2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.